We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Cadence Resubmits Pain Treatment Ofirmev NDA
Cadence Resubmits Pain Treatment Ofirmev NDA
May 5, 2010
Cadence Pharmaceuticals has resubmitted the NDA for its pain treatment Ofirmev, the company’s only investigational product candidate.